Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.

Authors :: Kuo AM
Hassoun H
Shah U
Gordon A
Hollmann TJ
Landau HJ
Lezcano C
Mailankody S
Tan CC
Lesokhin AM
Markova A
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2022 Sep; Vol. 63 (9), pp. 2233-2237. Date of Electronic Publication: 2022 May 09.
Publication Year :: 2022

Subjects :: Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Dexamethasone therapeutic use
Humans
Lenalidomide adverse effects
Exanthema drug therapy
Exanthema etiology
Multiple Myeloma complications
Multiple Myeloma drug therapy

Full Text Access

Tools